首頁 > 市場調查報告書 > 製藥

開發平台分析

市場調查報告書

商品編碼

1358056

組織纖溶酶原活化劑市場：依藥物類型、依用途、依地區

Tissue Plasminogen Activator Market, By Drug Type, By Application, By Geography

出版日期: 2023年09月20日 | 出版商:

Coherent Market Insights | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球組織纖溶酶原活化劑市場估計為25.8億美元，預計在預測期內（2023-2030年）年複合成長率為5.2%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	25.8億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	5.20%	2030年市場規模預測	36.8億美元

組織纖溶酶原活化劑全球市場佔有率(%)，依藥物類型，2023 年

組織纖溶酶原活化劑，也稱為組織型纖溶酶原活化劑(tPA)，是一種存在於內皮細胞（動脈內壁細胞）中的絲氨酸蛋白酶，參與分解血栓（纖維蛋白溶解）的過程。纖溶酶原經由 tPA 酶轉化為纖溶酶。 tPA 用於栓塞和血栓性中風研究。

tPA 可以使用重組生物技術生產。這種類型的 tPA 稱為重組組織纖溶酶原活化劑 (rtPA)。 t-PA 是一種存在於血液和組織中的蛋白水解酶。 t-PA 的主要生理功能是產生纖溶酶，從而破壞脈管系統中的血栓。

市場動態

由於組織纖溶酶原活化劑（tPA）用於治療缺血性中風，缺血性中風患病的增加預計將推動自由鑄造期的市場成長。例如，根據世界中風組織 (WSO) 的數據，到 2022 年，全球每年將新增超過 760 萬例缺血性中風。 2019年，缺血性中風佔全球中風的62%以上。近 11% 的缺血性中風發生在 15 至 49 歲的人群中。

此外，根據美國心臟協會 2022 年報告，2020 年全球約有 2.441 億人患有缺血性心臟疾病(IHD)。這種疾病在男性中更為常見，罹患約 1.41 億人，而女性估計為 1.031 億人。

本研究的主要特點

本報告對全球組織纖溶酶原活化劑市場進行了詳細分析，並提出了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率(CAGR)。
它還闡明了各個部門市場的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球組織纖溶酶原活化劑市場的主要企業。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場經營團隊和行銷策略做出明智的資訊。
全球組織纖溶酶原活化劑市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
透過用於分析全球組織纖溶酶原活化劑市場的各種策略矩陣，將促進相關人員的決策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 2.58 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.20%	2030 Value Projection:	US$ 3.68 Bn

Tissue plasminogen activator, also known as tissue-type plasminogen activator (tPA), is a serine protease that is present in endothelial cells, the cells that line blood arteries, and is involved in the process of breaking down blood clots (fibrinolysis). Plasminogen is transformed into plasmin by the tPA enzyme. tPA can be employed in studies on embolic or thrombotic stroke.

tPA may be produced by using recombinant biotechnology methods. This kind of tPA is known as recombinant tissue plasminogen activator (rtPA). t-PA is a proteolytic enzyme present in blood and tissues. The primary physiological function of t-PA is the production of plasmin that can break blood clots in the vasculature.

Market Dynamics

Increasing prevalence of ischemic stroke is expected to drive the market growth over frecast period as tissue-type plasminogen activator (tPA) is used to treat ischemic stroke. For instance, in 2022, according to World Stroke Organization (WSO), there are over 7.6 million new ischemic strokes each year worlwide. Ischemic strokes accounted for more than 62% of incident strokes worldwide in 2019. People aged 15 to 49 account for nearly 11% of all ischemic strokes each year.

Moreover, according to the 2022 report from the American Heart Association, there were approximately 244.1 million individuals globally living with ischemic heart disease (IHD) in the year 2020. This condition was found to be more prevalent among males, with approximately 141.0 million affected, compared to females, where the estimated number of affected individuals was 103.1 million.

Key features of the study:

This report provides an in-depth analysis of the global tissue plasminogen activator market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global tissue plasminogen activator market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global tissue plasminogen activator market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tissue plasminogen activator market

Detailed Segmentation:

By Drug Type:
- Alteplase
- Reteplase
- Tenecteplase
By Application:
- Ischemic Stroke
- Myocardial Infarction
- Pulmonary Embolism
- Thrombolysis
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- F. Hoffmann-La Roche AG.
- Boehringer Ingelheim GmbH
- CHIESI Farmaceutici S.p.A.
- Gennova Biopharmaceuticals Ltd
- Abbott Laboratories
- Reliance Life Sciences

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Application
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trend
Epidemiology
Key Developments
Regulatory Scenario
PEST Analysis
Pipeline Analysis
Acquisition and Collaboration Scenario

4. Global Tissue Plasminogen Activator Market- COVID-19 Impact Analysis

COVID-19 Epidemiology
Overall Impact on Healthcare Sector
Total Impact of COVID-19 on Global Tissue Plasminogen Activator Market
Government Recommendations

5. Global Tissue Plasminogen Activator Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Alteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030, (US$ Bn)
- Segment Trends
Reteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Tenecteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Tissue Plasminogen Activator Market, By Application, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Ischemic Stroke
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Myocardial Infarction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Pulmonary Embolism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Thrombolysis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Tissue Plasminogen Activator Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- U.S.
- Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- F. Hoffmann-La Roche AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Boehringer Ingelheim GmbH
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- CHIESI Farmaceutici S.p.A.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Gennova Biopharmaceuticals Ltd
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Abbott Laboratories
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Reliance Life Sciences
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies

9. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

纖溶(酉每)原的全球市場，實際成果與預測(2018年～2029年)

FAQ

組織纖溶酶原活化劑市場：依藥物類型、依用途、依地區

Tissue Plasminogen Activator Market, By Drug Type, By Application, By Geography

市場動態

目錄

第1章調查目的和假設

第2章市場展望

第3章市場動態、法規及趨勢分析

第4章全球組織纖溶酶原活化劑市場 - COVID-19 疾病的影響分析

第5章全球組織纖溶酶原活化劑市場，依藥物類型，2018-2030

第6章全球組織纖溶酶原活化劑市場，依用途，2018-2030

第7章全球組織纖溶酶原活化劑市場，依地區，2018-2030

第8章競爭形勢

第9章章節

Market Dynamics

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Tissue Plasminogen Activator Market- COVID-19 Impact Analysis

5. Global Tissue Plasminogen Activator Market, By Drug Type, 2018-2030, (US$ Bn)

6. Global Tissue Plasminogen Activator Market, By Application, 2018-2030, (US$ Bn)

7. Global Tissue Plasminogen Activator Market, By Region, 2018-2030, (US$ Bn)

8. Competitive Landscape

9. Section

組織纖溶酶原活化劑市場：依藥物類型、依用途、依地區

Tissue Plasminogen Activator Market, By Drug Type, By Application, By Geography

市場動態

目錄

第1章 調查目的和假設

第2章 市場展望

第3章 市場動態、法規及趨勢分析

第4章 全球組織纖溶酶原活化劑市場 - COVID-19 疾病的影響分析

第5章 全球組織纖溶酶原活化劑市場，依藥物類型，2018-2030

第6章 全球組織纖溶酶原活化劑市場，依用途，2018-2030

第7章 全球組織纖溶酶原活化劑市場，依地區，2018-2030

第8章 競爭形勢

第9章 章節

Market Dynamics

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Tissue Plasminogen Activator Market- COVID-19 Impact Analysis

5. Global Tissue Plasminogen Activator Market, By Drug Type, 2018-2030, (US$ Bn)

6. Global Tissue Plasminogen Activator Market, By Application, 2018-2030, (US$ Bn)

7. Global Tissue Plasminogen Activator Market, By Region, 2018-2030, (US$ Bn)

8. Competitive Landscape

9. Section

第1章調查目的和假設

第2章市場展望

第3章市場動態、法規及趨勢分析

第4章全球組織纖溶酶原活化劑市場 - COVID-19 疾病的影響分析

第5章全球組織纖溶酶原活化劑市場，依藥物類型，2018-2030

第6章全球組織纖溶酶原活化劑市場，依用途，2018-2030

第7章全球組織纖溶酶原活化劑市場，依地區，2018-2030

第8章競爭形勢

第9章章節